Parsons Brinckerhoff Lawrenceville, NJ Aug 2008 to Aug 2011 Engineer ITraffic Planning & Design Pottstown, PA Sep 2006 to Mar 2007 Transportation Engineering SpecialistHatch Mott McDonald Millburn, NJ Sep 2005 to Mar 2006 Engineering TechnicianTraffic Planning & Design Pottstown, PA Sep 2004 to Mar 2005 Transportation Engineer Specialist
Education:
New Jersey Institute of Technology Newark, NJ Dec 2011 Master of Science in Transportation PlanningDrexel University Philadelphia, PA Jun 2008 Bachelor of Science in Civil Engineering
Athens High School - General/Biology, Lincoln Land Community College - Biology
Relationship:
In_a_relationship
Tagline:
Im a 28 year old professional photographer from the Springfield Illinois. I am also a volunteer Firefighter/EMT. I will be updateing this as I have time anymore questions just ask.
Bragging Rights:
D&D PHOTOGRAPHY ~ OWNER
Andrew Dillon
Lived:
La Grande, Oregon Portland, Oregon Estacada, Oregon Fairview, Oregon
Education:
Reynolds High School
Andrew Dillon
Work:
Dillons Resturaunt - Dishwasher/Side Cook Fairhaven Little League - Umpire
Education:
Fairhaven High School
Andrew Dillon
Education:
Loyola University Chicago - Advertising/ PR
Andrew Dillon
Work:
I.D. Booth / Booth Electric Supply - Manager & Sales
About:
I'm currently managing the Corning, NY branch Of I.D. Booth/ Booth Electric Supply. Â I've been with Booth for 4 years but in the electrical supply business for 13.
Tagline:
Branch Manager Of Corning, NY Location
Andrew Dillon
Education:
Taylor University - Computer Science
Andrew Dillon
Flickr
News
NICE Reverses Stand on Abiraterone After Janssen Submits Additional Data
ng insufficient evidence to prove value. We know how important it is for patients to have the option to delay chemotherapy and its associated side effects, so we are disappointed not to be able to recommend abiraterone for use in this way, Andrew Dillon, chief executive of NICE, has said in a
Date: Mar 21, 2016
Category: Health
Source: Google
Roche's bid to sub Kadcyla for Herceptin takes a big hit with lackluster PhIII data
company's heralded breast cancer treatment was too expensive to cover. Roche proposed a discount to its list price, but Kadcyla costs 90,831 ($142,000) for a 14.5 month course of treatment, leaving it well above the cost-effectiveness threshold for cancer drugs, NICE CEO Andrew Dillon said at the time.
Date: Dec 19, 2014
Category: Health
Source: Google
NICE set to block use of 'unaffordable' new breast cancer drug
NICE chief executive Sir Andrew Dillon said he hoped Roche would act in the best interest of patients and use the consultation period to look again at their evidence and consider if there was more they could do.
The rationale for the draft guidelines is that the drug is very costly and it's not clear which patients are likely to benefit, according to Andrew Dillon, chief executive of the National Institute for Health & Clinical Excellence, which decides which drugs will be financed from public funds.